A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo Nivolumab Injection Combined Respectively With Fluorouracil Plus Cisplatin in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin; Fluorouracil
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shandong Boan Biotechnology
Most Recent Events
- 12 Mar 2024 Status changed from not yet recruiting to recruiting.
- 08 Sep 2023 New trial record